Sangamo delays readout for hemophilia A gene therapy

Sangamo Therapeutics Inc. (NASDAQ:SGMO) said on its 3Q18 earnings call on Nov. 8 that it will not submit a late-breaking abstract to present Phase I/II data for its hemophilia A gene therapy at next month's American Society of Hematology (ASH) meeting.

The gene therapy, SB-525, is a recombinant adeno-associated virus (rAAV) vector carrying a Factor VIII gene construct driven by a synthetic liver-specific promoter. Pfizer Inc. (NYSE:PFE) has exclusive, worldwide rights to the product from Sangamo...